Slide 1: NNIT Nordic Seminar 2016
NNIT Nordic Seminar 2016 SEB 7 January 2016
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar me
Slide 3: Leveraging our Novo Nordisk Heritage and Differentiated Compliance DNA
Leveraging our Novo Nordisk Heritage and Differentiated Compliance DNA to Win Profitable Market Shares Danish IT Market Leader Top 3 Leading market share in IT services market in Denmark and Fastest Growing Player (1) Global Delivery Model Market Share Winner with Historical Organic Revenue Growth 3
Slide 4: NNIT – who we are
NNIT – who we are Our Core Leveraging Our Compliance DNA Life Public Finance Enterprise Sciences DKK 1,547m DKK 326m DKK 166m DKK 371m (64%) (14%) (7%) (15%) See Note (1) DKK 743m (31%) IT Solutions Services: Advisory services, business solutions and application management DKK 1,667m (69%) IT Operat
Slide 5: The Key Pillars of Our Growth Strategy
The Key Pillars of Our Growth Strategy 1 Increase our share of existing customers’ IT spending 2 In Denmark Win new customers 2020 Strategy 3 Support Danish customers with their internationalization Win Profitable Market Share 4 Internationally Life Sciences Supporting Pillars 5 Continue our cost
Slide 6: Financial statement first nine month 2015
Financial statement first nine month 2015 Pct/pp Pct/pp 9M 2015 9M 2015 DKK million 9M 2014* Change Change (reported) (constant*) (reported) (constant) Revenue 1,877.4 1,862.1 1,721.6 9.0% 8.2% Cost of goods sold 1,518.4 1,481.9 1,389.3 9.3% 6.7% Gross profit 358.9 380.2 332.3 8.0% 14.4% Gross profi
Slide 7: Segment development first nine month 2015
Segment development first nine month 2015 Revenue Revenue Revenue Pct Change Pct Change DKKm 9M 2015 9M 2015 9M 2014* (reported) (constant) (reported) (constant*) Life Sciences 1,170.3 1,155.6 1,084.3 7.9% 6.6% Hereof Novo Nordisk Group 923.9 915.9 882.6 4.7% 3.8% Hereof other Life Sciences 246.4 23
Slide 8: Divisional P&L first nine month 2015
Divisional P&L first nine month 2015 IT Operation Pct/pp Pct/pp IT Operation 9M 2015 9M 2015 9M 2014* Change Change (reported) (constant*) DKK million (reported) (constant*) • Adjusted for discontinuation Revenue of re-invoicing of software Novo Nordisk Group 619.0 612.3 607.0 2.0% 0.9% licenses to
Slide 9: Backlog Provides Strong Visibility
Backlog Provides Strong Visibility
Slide 10: ..But Possible Clouds on the Horizon
..But Possible Clouds on the Horizon Traditionally high visibility growing to more than 70% of annual sales covered by the backlog at beginning of the year – long-term backlog increasing long-term visibility Cloud impact the backlog visibility in the future • Move from large long-term outsourcing SL
Slide 11: Outlook
Outlook 2015 Long-term Revenue 6-8% at constant currencies Target average growth in revenue of at growth Around 0.8pp higher as reported least 5% in constant currencies Operating Around 11% at constant currencies Target average operating profit margin of margin Around 1.3pp lower as reported at leas
Slide 12: Strong Expertise in Life Sciences and focused strategy
Strong Expertise in Life Sciences and focused strategy NNIT Delivers Value Added and Leading-edge Solutions tailored to Well- Recognized Pharmaceutical Groups by focusing… Pharma value chain Drug development Regulatory Affairs Regulatory driven Quality management Supply Chain Selected Tier
Slide 13: Life sciences in numbers
Life sciences in numbers 9 Month Pct Change 2015 (reported) DKK million (reported) 2014 Revenue 1.170,3 1.084,3 7,9% Hereof Novo Nordisk Group 923,9 882,6 4,7% Hereof other Life Sciences 246,5 201,7 22,2% Clients (in 2015): 34 – excl. China Clients in China (in 2015): 10 *Excl. Novo Nordisk
Slide 14: Investor contact information
Investor contact information Upcoming events 7 January 2016: Presentation at SEB Nordic Seminar, Copenhagen 27 January 2016: Full year 2015 reporting 11 March 2016: Annual General Meeting 13 May 2016: Interim report for the period 1 January 2016 – 31 March 2016 Investor contact NNIT A/S Østmarken 3A